Ripretinib

Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) [1][2]. DCC-2618 exerts antineoplastic effect and induces apoptosis[3].

Product Specifications

CAS Number

[1442472-39-0]

Product Name Alternative

DCC-2618

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Apoptosis; c-Kit; FLT3; PDGFR; VEGFR

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/DCC-2618.html

Purity

98.90

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC(C2=CC3=C(C=C(NC)N=C3)N(CC)C2=O)=C(Br)C=C1F)NC4=CC=CC=C4

Molecular Formula

C24H21BrFN5O2

Molecular Weight

510.36

Precautions

H315, H319, H320

References & Citations

[1]KIT/PDGFR Inhibitor DCC-2618.|[2]BLU-285, DCC-2618 Show Activity against GIST. Cancer Discov. 2017 Feb;7 (2) :121-122.|[3]Schneeweiss M, et al. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018 May;103 (5) :799-809.